All In Biotech

Drug Trial Radar · NCT01653678

Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)

Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and Hypertension

Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 25,875 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

25,875

Actual

Start

Nov 2011

Primary completion

Nov 2025

Study completion Jun 2026

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Jul 31, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The VITAL Hypertension ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids are related to changes in blood pressure and hypertension.

Conditions

  • Hypertension

Interventions

  • Vitamin D-3 (cholecalciferol), 2000 IUDietary supplement

  • Omega-3 fatty acids (fish oil)Drug

    Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

  • Vitamin D placeboDietary supplement

  • Fish oil placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in blood pressureTime frame: Two years
  2. Incident hypertensionTime frame: 5 years
  3. Changes in 25-hydroxy-vitamin D levelsTime frame: 2 years
  4. Changes in fatty acid levelsTime frame: 2 years
  5. Changes in biomarkers related to blood pressureTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.